Safety and Cost Concerns Cloud Early Promise of New Cancer Drugs

A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells are proving to be highly effective weapons against tumors, but top oncology researchers are concerned about the two emerging technologies, citing dangers seen repeatedly in clinical trials, including the potentially fatal buildup of toxic debris from killed tumor cells and damage to healthy tissues, according to a new report from Reuters. Such adverse effects could block regulatory approval if they aren't controlled, researchers and drug company executives told Reuters reporters.

http://ift.tt/1zr13xy